EP0749313A4 - Verfahren zur behandlung von mit dem 5-ht2b-rezeptor verbundenen zuständen - Google Patents

Verfahren zur behandlung von mit dem 5-ht2b-rezeptor verbundenen zuständen

Info

Publication number
EP0749313A4
EP0749313A4 EP95914014A EP95914014A EP0749313A4 EP 0749313 A4 EP0749313 A4 EP 0749313A4 EP 95914014 A EP95914014 A EP 95914014A EP 95914014 A EP95914014 A EP 95914014A EP 0749313 A4 EP0749313 A4 EP 0749313A4
Authority
EP
European Patent Office
Prior art keywords
states related
ht2b receptor
treating states
treating
ht2b
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95914014A
Other languages
English (en)
French (fr)
Other versions
EP0749313A1 (de
Inventor
James Edmund Audia
Marlene Lois Cohen
Jaswant Singh Gidda
David Lloyd Garver Nelson
Stephen Richard Baker
Jesus Ezquerra-Carrera
Carlos Lamas-Peteira
Concepcion Pedregal-Tercero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/380,566 external-priority patent/US5688807A/en
Priority claimed from US08/380,565 external-priority patent/US5663178A/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of EP0749313A1 publication Critical patent/EP0749313A1/de
Publication of EP0749313A4 publication Critical patent/EP0749313A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigation Of Foundation Soil And Reinforcement Of Foundation Soil By Compacting Or Drainage (AREA)
  • Liquid Crystal Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP95914014A 1994-03-11 1995-03-10 Verfahren zur behandlung von mit dem 5-ht2b-rezeptor verbundenen zuständen Withdrawn EP0749313A4 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US380565 1989-07-14
US21262294A 1994-03-11 1994-03-11
US212622 1994-03-11
US380566 1995-02-06
US08/380,566 US5688807A (en) 1994-03-11 1995-02-06 Method for treating 5HT2B receptor related conditions
US08/380,565 US5663178A (en) 1995-02-06 1995-02-06 Tetrahydro-beta carbolines
PCT/US1995/003099 WO1995024200A1 (en) 1994-03-11 1995-03-10 Method for treating 5ht2b receptor related conditions

Publications (2)

Publication Number Publication Date
EP0749313A1 EP0749313A1 (de) 1996-12-27
EP0749313A4 true EP0749313A4 (de) 2001-10-24

Family

ID=27395770

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95914014A Withdrawn EP0749313A4 (de) 1994-03-11 1995-03-10 Verfahren zur behandlung von mit dem 5-ht2b-rezeptor verbundenen zuständen

Country Status (11)

Country Link
EP (1) EP0749313A4 (de)
JP (1) JPH09510216A (de)
CN (1) CN1148340A (de)
AU (1) AU679635B2 (de)
CA (1) CA2185236A1 (de)
CZ (1) CZ264996A3 (de)
FI (1) FI963571A7 (de)
HU (1) HUT75522A (de)
IL (1) IL112958A0 (de)
NO (1) NO963785L (de)
WO (1) WO1995024200A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
WO1996032944A1 (en) * 1995-04-18 1996-10-24 Eli Lilly And Company Method for using ergoline compounds to effect physiological and pathological functions at the 5-ht7 receptor
GB9523999D0 (en) 1995-11-23 1996-01-24 Lilly Co Eli Indolyl neuropeptide y receptor antagonists
JP2000507269A (ja) * 1996-03-15 2000-06-13 イーライ・リリー・アンド・カンパニー 一般かぜまたはアレルギー性鼻炎の処置方法
US5880134A (en) * 1996-03-20 1999-03-09 Eli Lilly And Company Method for using ergoline compounds to effect physiological and pathological functions at the 5-HT7 receptor
US5886003A (en) * 1996-03-25 1999-03-23 Eli Lilly And Company Methods of treating or ameliorating the symptoms of venomous bites and stings
BR9708145A (pt) * 1996-03-25 1999-07-27 Lilly Co Eli Processo para tratamento de dor de enxaqueca
IL126062A0 (en) * 1996-03-25 1999-05-09 Lilly Co Eli Tetrahydrobetacarboline compounds
AU4856600A (en) 1999-05-18 2000-12-05 Synaptic Pharmaceutical Corporation Use of agonists or antagonists of the 5-ht7 receptor to treat disorders of the bladder
JP3893878B2 (ja) 1999-05-24 2007-03-14 三菱ウェルファーマ株式会社 フェノキシプロピルアミン化合物
US6444477B1 (en) * 2000-11-28 2002-09-03 Pharmagene Laboratories Limited Assay method for detecting 5-HT2B antagonists
GB0203412D0 (en) 2002-02-13 2002-04-03 Pharmagene Lab Ltd 5-HT 2B receptor antagonists
JP2006525972A (ja) * 2003-05-09 2006-11-16 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ 食物摂取障害の予防および／または治療用の医薬品製造のためのスルホンアミド誘導体の使用
US20080171788A1 (en) * 2005-02-08 2008-07-17 Shinobu Akuzawa Medicament For Irritable Bowel Syndrome
EP1923387B1 (de) 2005-08-08 2011-10-19 Astellas Pharma Inc. Acylguanidinderivat oder salz davon
WO2007097276A1 (ja) * 2006-02-20 2007-08-30 Astellas Pharma Inc. ピロール誘導体またはその塩
TWI443098B (zh) 2008-03-24 2014-07-01 Medivation Technologies Inc 吡啶并〔３，４－ｂ〕吲哚及使用方法
RU2528406C2 (ru) 2008-11-21 2014-09-20 Раквалиа Фарма Инк. Новое производное пиразол-3-карбоксамида, обладающее антагонистической активностью в отношении рецептора 5-нт2в
TW201038569A (en) * 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
EP2480079A4 (de) * 2009-09-23 2015-04-08 Medivation Technologies Inc Pyrido-(3,4-b-)indole und verwendungsverfahren dafür
AU2010298168B2 (en) 2009-09-23 2015-11-19 Medivation Technologies, Inc. Pyrido(3,4-b)indoles and methods of use
KR20220071293A (ko) 2016-04-01 2022-05-31 리커리엄 아이피 홀딩스, 엘엘씨 에스트로겐 수용체 조절제
EP3519816A4 (de) 2016-09-29 2020-05-06 The Regents of the University of California Verbindungen zur erhöhung der neuronalen plastizität
WO2020176597A1 (en) * 2019-02-27 2020-09-03 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
KR102946120B1 (ko) 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
JP2022543832A (ja) 2019-08-06 2022-10-14 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 変異体を治療するためのエストロゲン受容体調節剤
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
MX2023002557A (es) * 2020-09-01 2023-05-29 Enveric Biosciences Canada Inc Derivados de psilocibina halogenada y metodos de uso.
WO2022221415A2 (en) 2021-04-13 2022-10-20 The Regents Of The University Of California Tetracyclic compounds for treating brain disorders
CN117677618A (zh) * 2021-04-23 2024-03-08 吉尔伽美什制药公司 新颖的麦角灵类和治疗心境障碍的方法
WO2023018864A1 (en) 2021-08-12 2023-02-16 Psilosterics, Llc Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same
JP2025502615A (ja) 2021-12-15 2025-01-28 デリックス セラピューティクス，インク． フェノキシおよびベンジルオキシ置換サイコプラストゲンならびにその使用
CA3238440A1 (en) 2021-12-30 2023-07-06 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
WO2023143393A1 (zh) * 2022-01-29 2023-08-03 上海科技大学 三并环类化合物、其制备方法和用途
WO2025137581A1 (en) * 2023-12-21 2025-06-26 Atai Therapeutics, Inc. Novel tetrahydro pyridine substituted indole and azaindoles, compositions of matter and pharmaceutical compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3492304A (en) * 1968-06-24 1970-01-27 Warner Lambert Pharmaceutical 5,6,7,7a,8,8a,9,10,12,12a-decahydro-11h-benz(b)indolo(3,2,1-ij) 1,5 naphthyridin-11-ones
US4731358A (en) * 1982-10-29 1988-03-15 Schering Aktiengesellschaft β-carbolines and their use as tranquilizers
US5300645A (en) * 1993-04-14 1994-04-05 Eli Lilly And Company Tetrahydro-pyrido-indole
EP0620222A2 (de) * 1993-04-14 1994-10-19 Eli Lilly And Company Tetrahydro-betacarboline

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4520024A (en) * 1983-02-11 1985-05-28 Eli Lilly And Company Method of selectively blocking peripheral vascular serotonergic receptors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3492304A (en) * 1968-06-24 1970-01-27 Warner Lambert Pharmaceutical 5,6,7,7a,8,8a,9,10,12,12a-decahydro-11h-benz(b)indolo(3,2,1-ij) 1,5 naphthyridin-11-ones
US4731358A (en) * 1982-10-29 1988-03-15 Schering Aktiengesellschaft β-carbolines and their use as tranquilizers
US5300645A (en) * 1993-04-14 1994-04-05 Eli Lilly And Company Tetrahydro-pyrido-indole
EP0620222A2 (de) * 1993-04-14 1994-10-19 Eli Lilly And Company Tetrahydro-betacarboline

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AUDIA, J. E. ET AL.: "Potent, selective tetrahydro-beta-carboline antagonists of the serotonin 2B contractile receptor in the rat stomach fundus", J. MED. CHEM., vol. 39, 1996, pages 2773 - 2780, XP002167539 *
GLENNON, R. A.: "Central Serotonin Receptors as Targets for Drug Research", J. MED. CHEM., vol. 30, 1987, pages 1 - 12, XP002167538 *
MARTIN G R ET AL: "RECEPTORS FOR 5-HYDROXYTRYPTAMINE: CURRENT PERSPECTIVES ON CLASSIFICATION AND NOMENCLATURE", NEUROPHARMACOLOGY,GB,PERGAMON PRESS, OXFORD, vol. 33, no. 3/04, 1 March 1994 (1994-03-01), pages 261 - 273, XP002037183, ISSN: 0028-3908 *
ONDA, M.; KAWANISHI, M.: "Analogs of Rauwolfia Alkaloids", J. PHARM. SOC. JPN., vol. 76, 1956, pages 966 - 968, XP000985848 *
See also references of WO9524200A1 *
SPÄTH, E. ET AL: "SYNTHESEN VON 4-CARBOLINEN", CHEMISCHE BERICHTE,XX,XX, vol. 120, 18 July 1930 (1930-07-18), pages 2102 - 2111, XP000917524, ISSN: 0009-2940 *

Also Published As

Publication number Publication date
HU9602482D0 (en) 1996-11-28
NO963785L (no) 1996-11-01
FI963571A0 (fi) 1996-09-10
CN1148340A (zh) 1997-04-23
AU2118695A (en) 1995-09-25
HUT75522A (en) 1997-05-28
FI963571L (fi) 1996-11-08
FI963571A7 (fi) 1996-11-08
WO1995024200A1 (en) 1995-09-14
JPH09510216A (ja) 1997-10-14
AU679635B2 (en) 1997-07-03
CZ264996A3 (cs) 1998-01-14
IL112958A0 (en) 1995-06-29
CA2185236A1 (en) 1995-09-14
EP0749313A1 (de) 1996-12-27
NO963785D0 (no) 1996-09-10

Similar Documents

Publication Publication Date Title
DE69331469D1 (de) Verfahren zur behandlung von abfällen
DE69807868D1 (de) Verfahren zur behandlung von abwasserstroemen
DE69425372D1 (de) Verfahren zur behandlung endo-ostealer materialien
DE69420339D1 (de) Verfahren zur Behandlung einer Flüssigkeit
DE69627642D1 (de) Verfahren zum herstellen von pflasterungen
DE69701714D1 (de) Verfahren zur behandlung von glassubstraten
AT399887B (de) Verfahren zum herstellen von kaltgepressten eisenhältigen briketts
DE69222396D1 (de) Verfahren zum Aufbereiten von Kohlenwasserstoffen
DE69304233D1 (de) Vorrichtung zur Behandlung von Wasser
FI963571L (fi) Menetelmä 5HT2B-reseptoriin liittyvien tilojen hoitamiseksi
DE69421196D1 (de) Vorrichtung zur behandlung von überbiss
DE69427774D1 (de) Kontinuierliches verfahren zur behandlung von nahrungsmitteln
DE59810532D1 (de) Verfahren zur behandlung von cellulosischen formkörpern
DE59601109D1 (de) Verfahren zum behandeln von hausmüll
DE69522745D1 (de) Verfahren zum Abbau von Polysiloxanen
DE69607559D1 (de) Verfahren zur Behandlung von Phenolteer
DE59500527D1 (de) Verfahren zum Stabilisieren von Organopolysiloxanen
DE69709419D1 (de) Verfahren zur Behandlung von Abwasser
DE58902128D1 (de) Verfahren zur behandlung von klaerschlamm.
DE69609082D1 (de) Verfahren zur behandlung von abfällen
DE69706758D1 (de) Verfahren zur Behandlung von Polyolefin
DE59308384D1 (de) Verfahren zur Behandlung von Gülle
DE69307803D1 (de) Verfahren zur elektrolytischen Behandlung
DE69802904D1 (de) Verbessertes verfahren zur behandlung von aluminiummonohydratreichen bauxiten
DE69504476D1 (de) Verfahren zum herstellen von polyflouroxetanen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960911

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 960911;SI PAYMENT 960911

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 471/04 A, 7C 07D 209/16 B, 7C 07D 457/04 B, 7C 07D 457/06 B, 7C 07D 241/04 B, 7C 07D 403/12 B, 7C 07D 261/08 B, 7A 61K 31/551 B

A4 Supplementary search report drawn up and despatched

Effective date: 20010911

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20011203